Cargando…

Comparison of tolvaptan treatment between patients with the SIADH and congestive heart failure: a single-center experience

BACKGROUND/AIMS: Tolvaptan is a very effective treatment for hypervolemic or euvolemic hyponatremia. We compared the clinical efficacy of and response to tolvaptan in patients with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and congestive heart failure (CHF). METHODS: We re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Gun Ha, Lee, Chang Min, Song, Jae Won, Jung, Moon Chan, Kim, Jwa Kyung, Song, Young Rim, Kim, Hyung Jik, Kim, Sung Gyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943653/ https://www.ncbi.nlm.nih.gov/pubmed/28286940 http://dx.doi.org/10.3904/kjim.2016.155

Ejemplares similares

THU239 Tolvaptan For SIADH Management In Children
por: Igarashi, Mizuho, et al.
Publicado: (2023)

Impact of rapid ultrafiltration rate on changes in the echocardiographic left atrial volume index in patients undergoing haemodialysis: a longitudinal observational study
por: Kim, Jwa-Kyung, et al.
Publicado: (2017)

Long-term prognosis of end-stage renal disease patients with normal myocardial perfusion as determined by single photon emission computed tomography
por: Park, Gun Ha, et al.
Publicado: (2018)

Tolvaptan use during hyperhydration in paediatric intracranial lymphoma with SIADH
por: Willemsen, Ruben H, et al.
Publicado: (2016)

Long-term low-dose tolvaptan efficacy and safety in SIADH
por: Bondanelli, Marta, et al.
Publicado: (2023)

Cardiac risk assessment by gated single-photon emission computed tomography in asymptomatic end-stage renal disease patients at the start of dialysis
por: Kim, Jwa-Kyung, et al.
Publicado: (2011)

Efficacy and safety of intravenous OPC‐61815 compared with oral tolvaptan in patients with congestive heart failure
por: Sato, Naoki, et al.
Publicado: (2022)

In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis
por: Humayun, Malik Asif, et al.
Publicado: (2017)

Excessive Weight Gain during the First Year of Peritoneal Dialysis Is Associated with Inflammation, Diabetes Mellitus, and a Rapid Decrease in Residual Renal Function
por: Kim, Jwa-Kyung, et al.
Publicado: (2015)

Clinical significance of subclinical carotid atherosclerosis and its relationship with echocardiographic parameters in non-diabetic chronic kidney disease patients
por: Kim, Jwa-Kyung, et al.
Publicado: (2013)

High pulse pressure and metabolic syndrome are associated with proteinuria in young adult women
por: Kim, Jwa-Kyung, et al.
Publicado: (2013)

The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure
por: Otsuka, Tomoyuki, et al.
Publicado: (2013)

A case report with shock induced by tolvaptan in an elderly patient with congestive heart failure
por: Zhang, Zhi-gang, et al.
Publicado: (2018)

Vitamin D: a possible modifying factor linking obesity to vascular calcification in hemodialysis patients
por: Kim, Jwa-Kyung, et al.
Publicado: (2017)

SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan
por: De las Peñas, Ramón, et al.
Publicado: (2015)

Increased Neutrophil Extracellular Trap Formation in Uremia Is Associated with Chronic Inflammation and Prevalent Coronary Artery Disease
por: Kim, Jwa-Kyung, et al.
Publicado: (2017)

Late stage 3 chronic kidney disease is an independent risk factor for sarcopenia, but not proteinuria
por: An, Jung Nam, et al.
Publicado: (2021)

Serum cystatin C to creatinine ratio is associated with sarcopenia in non-dialysis-dependent chronic kidney disease
por: An, Jung Nam, et al.
Publicado: (2022)

Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia Resulting from SIADH Following Pituitary Surgery
por: Kleindienst, Andrea, et al.
Publicado: (2020)

Case Report: Long-Term Tolvaptan Treatment in a Child With SIADH and Suprasellar Arachnoid Cyst
por: Puma, Andrea, et al.
Publicado: (2021)

Outcomes of vascular access in hemodialysis patients: Analysis based on the Korean National Health Insurance Database from 2008 to 2016
por: Lee, Hyung Seok, et al.
Publicado: (2019)

Increased body fat rather than body weight has harmful effects on 4-year changes of renal function in the general elderly population with a normal or mildly impaired renal function
por: Kim, Jwa-Kyung, et al.
Publicado: (2014)

Right ventricular enlargement predicts responsiveness to tolvaptan in congestive heart failure patients with reduced ejection fraction
por: Nonin, Shinichi, et al.
Publicado: (2018)

Benefit of tolvaptan in the management of hyponatraemia in patients with diuretic‐refractory congestive heart failure: the SEMI‐SEC project
por: Pose, Antonio, et al.
Publicado: (2017)

Neutrophil extracellular traps and heparin-induced antibodies contribute to vascular access thrombosis in hemodialysis patients
por: Lee, Hoi Woul, et al.
Publicado: (2021)

Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis
por: Wu, Mei-Yi, et al.
Publicado: (2017)

A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan
por: Petereit, Claudia, et al.
Publicado: (2013)

Tolvaptan, hyponatremia, and heart failure
por: Zmily, Hammam D, et al.
Publicado: (2011)

Four-Year Changes in Visceral Fat Mass and the Risk of Developing Proteinuria in the General Population
por: Kim, Jwa-Kyung, et al.
Publicado: (2015)

Acute kidney injury can predict in-hospital and long-term mortality in elderly patients undergoing hip fracture surgery
por: Hong, Seong Eun, et al.
Publicado: (2017)

SIADH Associated with Prostate Cancer
por: Lee, Kyun Sang, et al.
Publicado: (2007)

Impact of sarcopenia on long-term mortality and cardiovascular events in patients undergoing hemodialysis
por: Kim, Jwa-Kyung, et al.
Publicado: (2019)

Correction: Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis
por: Wu, Mei-Yi, et al.
Publicado: (2019)

The role of tolvaptan in managing hyponatremia in small cell lung cancer patients with SIADH: a retrospective study of 23 cases
por: Ren, Peng, et al.
Publicado: (2021)

Current treatment status and medical costs for hemodialysis vascular access based on analysis of the Korean Health Insurance Database
por: Lee, Hyung Seok, et al.
Publicado: (2018)

Role of peribrachial fat as a key determinant of brachial artery dilatation for successful arteriovenous fistula maturation in hemodialysis patients
por: Lee, Hyung Seok, et al.
Publicado: (2020)

Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2016)

Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure
por: Kiuchi, Shunsuke, et al.
Publicado: (2018)

Serum levels of protein carbonyl, a marker of oxidative stress, are associated with overhydration, sarcopenia and mortality in hemodialysis patients
por: Song, Young Rim, et al.
Publicado: (2020)

Tolvaptan: A Novel Diuretic in Heart Failure Management
por: Zulkifli Amin, Hilman, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2eja59fvqis91cibi5fubuq34g